MARKSANS
1 call
Concalls & earnings callsMarksans Pharma Limited
Every summarised call, newest first. Latest is Q1 FY27, held 13 Aug 2026.
Latest quarter
Q1 FY27 snapshot
Open full brief →The company started FY27 with record quarterly revenue, EBITDA, and PAT, driven by strong European growth via acquisitions and organic expansion across all geographies.
| Metric | This quarter | Change | Five-quarter trend |
|---|---|---|---|
| Revenue | ₹840.8 Cr | 35.6% | |
| EBITDA | ₹213 Cr | 112.8% | |
| PAT | ₹159.4 Cr | 173.9% | |
| Cash Balance | ₹1,058 Cr | — |
Latest guidance
- Full-year revenue growth of 15% to 20%.
- Full-year EBITDA margin of 20% to 21%.
- Expect to reach revenue of INR4,000 crores within the next two years.
- Expect QliniQ to do around INR150-175 crores revenue for the full year.
- Expect Europe revenue to be around INR180 crores for the year.
- Aiming to double product portfolio in every country within 2-3 years.
Said on the Q1 FY27 call.
Filed results
Reported quarterly history
From filed quarterly results. YoY and QoQ compare each metric on the same accounting basis.
| Quarter | Revenue | Net profit (PAT) | Basic EPS |
|---|---|---|---|
| Q3 FY25 | ₹681.85 Cr+16.3% YoY+6.2% QoQ | ₹105.07 Cr+26.6% YoY+7.5% QoQ | ₹2.31+25.5% YoY+8.5% QoQ |
| Q2 FY25 | ₹641.92 Cr+20.8% YoY+8.7% QoQ | ₹97.76 Cr+16.6% YoY+9.8% QoQ | ₹2.13+15.8% YoY+8.7% QoQ |
| Q1 FY25 | ₹590.62 Cr+18.1% YoY+5.5% QoQ | ₹89.07 Cr+26.4% YoY+14.7% QoQ | ₹1.96+28.9% YoY+13.3% QoQ |
| Q4 FY24 | ₹560.01 Cr+15.2% YoY-4.5% QoQ | ₹77.64 Cr-6.1% YoY-6.4% QoQ | ₹1.73-12.2% YoY-6% QoQ |
| Q3 FY24 | ₹586.13 Cr+22.2% YoY+10.3% QoQ | ₹82.97 Cr+33.2% YoY-1% QoQ | ₹1.84+17.9% YoY0% QoQ |
Call history
- Q1 FY27Positive tone
The company started FY27 with record quarterly revenue, EBITDA, and PAT, driven by strong European growth via acquisitions and organic expansion across all geographies.
- Revenue
- ₹840.8 Cr35.6%
- EBITDA
- ₹213 Cr112.8%